Biomarkers Market to Reach $112.10 Billion by 2031

The global biomarkers market is forecast to reach $112.10 billion by 2031, up from an estimated $67.95 billion in 2026. The market is expected to grow at a compound annual growth rate (CAGR) of 10.5% over this period.

Growth drivers include the rising prevalence of diseases such as cancer, cardiovascular conditions, and neurological disorders, coupled with increased investments in medical research and development. Biomarkers are crucial for disease diagnosis, prognosis, and monitoring treatment efficacy.

Demand for cancer biomarkers is particularly strong, as they enable the development of more targeted and effective therapies. Pharmaceutical and diagnostic companies are investing heavily in identifying and leveraging novel biomarkers for drug discovery and personalized medicine.

North America is currently the largest market, driven by advanced healthcare infrastructure and R&D activities. The Asia-Pacific region is anticipated to witness significant growth due to increasing healthcare expenditure and awareness.